Marinus Pharma (MRNS) Commences Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder
Tweet Send to a Friend
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) today announced the initiation of a pivotal Phase 3 clinical trial (Marigold Study) evaluating the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
